13 August 2018
Visiongain has launched a new pharma report Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers, 2017-2027, and Other Rising Companies – a Market Report Assessing Developers and Producers of Competitor Biologics
The EU defines a biological medicinal product as “a protein or nucleic acid-based pharmaceutical substance used for therapeutic or in vivo diagnostic purposes, which is produced by means other than direct extraction from a native (non-engineered) biological source.”
A Biosimilar is a biological medicinal product that contains a version of the active substance of an original approved biologic. These are typically released after the original patent expires. A Biosimilar demonstrates similarity to the reference medicinal product in terms of biological activity, safety and efficacy. The quality of a biologic product is defined by its manufacturing process. Minor changes in the process can affect the quality, functionality and stability of the drug substance in the product, in turn affecting its biological activity.
The lead Visiongain report analyst for this report commented “Recently, biosimilars have increasingly gained popularity. This is mainly attributed to their lower prices in comparison with the original biologics. With more and more blockbuster drugs coming off patent, the biosimilars market has experienced immense growth, which will continue further, at a rapid pace. Biosimilars give more competition and opportunities in the biological drugs market by attracting new market entrants. Those competitors include biopharma and generics specialists, as well as leading international pharmaceutical companies.
This increased competition will prove beneficial to the biosimilars market, as it will drive innovation and lead to more-efficient methods of production with lower costs, which will help more people have access to affordable medical care. The striving for affordable healthcare has driven the biosimilars market to grow fastest in some developing countries. This has resulted in Indian and Chinese biosimilar companies making their mark as leading biosimilar drug producers and competing with the capabilities of market leaders based in the developed countries for pharmaceutical production.
Furthermore, the biosimilars market is characterised by numerous partnerships and collaborations among the well-established and rising firms, leading to overall growth in that industry through a combination of innovation and financial backing”
Growth is expected to be rapid during the first-half of the forecasted period due to the patent cliff from years 2012-2019, which will see the patent expiry of many of the most popular biologics in the world.
Leading companies who are active in the Biosimilars market and are featured in the report include: 3SBio, Amega Biotech, Beijing ShuangLu Pharmaceuticals, Biocad Biocon, Biosidus, Bioton, Celltrion, Dong-A, Dr Reddy’s Laboratiories, Intas Biopharmaceutical, LG Life Sciences, Mylan, Probiomed, Qilu Pharmaceutical, Ranbaxy (Sun Pharma), Reliance Life Science, Sandoz (Novartis), Shanghai Fosun Pharmaceuticals, STADA Arzneimittel, Teva, Hospira (Pfizer), Tonghua Dongbao, Wockhardt, and Zydus Cadila. In addition to these companies, the report also features upcoming companies in the biosimilar market in each major region.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.